HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

prostate-specific antigen (154-163)

Also Known As:

PSA 154-163

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Seminal Proteins: 8
    - Seminal Plasma Proteins: 25
      - Prostatic Secretory Proteins: 4
        Prostate-Specific Antigen: 15321
        prostate-specific antigen (154-163): 1
- Peptides: 82426
  - Peptide Fragments: 373
    - prostate-specific antigen (154-163): 1
Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Hydrolases: 2166
    - Peptide Hydrolases: 23957
      - Serine Proteases: 3726
        Serine Endopeptidases: 11
        Kallikreins: 2114
        Prostate-Specific Antigen: 15321
        prostate-specific antigen (154-163): 1
      - Endopeptidases: 633
        Serine Endopeptidases: 11
        Kallikreins: 2114
        Prostate-Specific Antigen: 15321
        prostate-specific antigen (154-163): 1
Biological Factors: 2472
- Biomarkers: 240291
  - Tumor Biomarkers: 15272
    - Prostate-Specific Antigen: 15321
      - prostate-specific antigen (154-163): 1
- Antigens: 143924
  - Neoplasm Antigens: 6217
    - Prostate-Specific Antigen: 15321
      - prostate-specific antigen (154-163): 1

Experts

1.	Alexander, Richard B: 1 article (07/2009)
2.	Berard, Carla A: 1 article (07/2009)
3.	Datena, Ellen: 1 article (07/2009)
4.	Dawson, Nancy: 1 article (07/2009)
5.	Hussain, Arif: 1 article (07/2009)
6.	Klyushnenkova, Elena N: 1 article (07/2009)
7.	Kouiavskaia, Diana V: 1 article (07/2009)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 07/01/2009 - "Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer." 07/01/2009 - "We conducted a clinical trial of peptide prostate specific antigen (PSA): 154-163 (155L) vaccination in human leukocyte antigen (HLA)-A2 patients with detectable and rising serum PSA after radical prostatectomy for prostate cancer (Clinicaltrials.gov identifier NCT00109811). "
2.	Neoplasms (Cancer) 07/01/2009 - "Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer."

Related Drugs and Biologics

1.	Prostate-Specific Antigen (Semenogelase)
2.	Peptides (Polypeptides)
3.	HLA Antigens (Human Leukocyte Antigens)

Related Therapies and Procedures

1.	Prostatectomy (Retropubic Prostatectomy)